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Abstract
Veterans of infection, Leishmania parasites have been plaguing mammals for centuries, causing a morbidity toll second only to that of malaria
as the most devastating protozoan parasitic disease in the world. Cutaneous leishmaniasis (CL) is, by far, the most prevalent form of the
disease, with symptoms ranging from a single self-healing lesion to chronic metastatic leishmaniasis (ML). In an increasingly
immunocompromised population, complicated CL is becoming a more likely outcome, characterized by severely inﬂamed, destructive
lesions that are often refractory to current treatment. This is perhaps because our ageing arsenal of variably effective antileishmanial drugs
may be directly or indirectly immunomodulatory and may thus have variable effects in each type and stage of CL. Indeed, widely differing
immune biases are created by the various species of Leishmania, and these immunological watersheds are further shifted by extrinsic
disturbances in immune homeostasis. For example, we recently showed that a naturally occurring RNA virus (Leishmania RNA virus (LRV))
within some Leishmania parasites creates hyperinﬂammatory cross-talk, which can predispose to ML: a case of immunological misﬁre that
may require a different approach to immunotherapy, whereby treatments are tailored to underlying immune biases. Understanding the
intersecting immune pathways of leishmaniasis and its co-infections will enable us to identify new drug targets, and thereby design
therapeutic strategies that work by untangling the immunological cross-wires of pathogenic cross-talk.
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This review evaluates the possible incidence and effects of
pathogenic cross-talk in cutaneous leishmaniasis, as well as its
potential in antileishmanial therapy.
Introduction
Veterans of infection, Leishmania parasites have been plaguing
mammals for centuries. After malaria, leishmaniasis is the most
important protozoan parasitic disease in the world, with
350 million people being at risk on ﬁve continents in 98
countries, and is steadfastly listed in the top ten most
debilitating infectious diseases in the world (according to
disability-adjusted life-years) [1–3]. Despite its staggering
prevalence and morbidity, it has been categorized as a
‘neglected disease’, with little clinical research interest, no
vaccine, and a vastly inadequate therapeutic arsenal. Thus, the
missing noses, drooping lips and agonizingly disﬁgured faces
depicted on pre-Inca pottery are, astonishingly, still relevant
today as current prognoses (Fig. 1, inset).
Leishmania parasites are vectored as promastigotes in a
haematophagous sand ﬂy and regurgitated into the human
epidermis during a blood meal. Host macrophages are quick
to innately quarantine parasites into phagolysosomes, which
kill intracellular pathogens by compartmentalized oxidative
stress. Often, however, the parasites not only survive in this
hostile territory, but thrive, employing intricate immune
evasion tactics to complete their life cycle as replicating
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amastigotes. The disease has various symptomatic outcomes,
ranging from a single self-healing cutaneous lesion at the site of
inoculation (cutaneous leishmaniasis (CL)) to a metastasizing
dissemination of chronic, disﬁguring inﬂammation (metastatic
leishmaniasis (ML)). Furthermore, one-quarter of all infections
are potentially fatal, disseminating to non-dermal, vital tissues,
such as the liver, spleen, and bonemarrow (visceral leishmaniasis
(VL), which is responsible for at least 50 000 deaths per year).
These vastly different outcomes follow geographical patterns,
branching with the speciation of Leishmania (Fig. 1).
This phylogenetic clustering supports the idea that symp-
tomatic tropism is determined by species-speciﬁc parasite
factors. For example, parasites causing VL are thought to
harbour a ‘visceralizing factor’. The A2 gene was proposed as
such a candidate, enabling parasites to withstand the heat
shock of visceral fever [4,5]. Indeed, genetic introduction of
A2 into the non-visceralizing parasite Leishmania major
supported visceral colonization and heat tolerance [6].
Interestingly, a functional A2 protein is also found in the
non-visceralizing exception of Leishmania mexicana, indicating
that visceralization is a multifactorial process and could be
different between Old World and New World species [7].
Interestingly, although the Leishmania Viannia subgroup in
South America is almost exclusively responsible for mucocu-
taneous metastasis, no obvious or common ‘metastatic
factors’ have been found within the group. Recently, we
were able to correlate disease severity in members of
L. Viannia with the presence of an endosymbiotic RNA virus
in their cytoplasm (Leishmania RNA virus (LRV)) [8–11].
Here, the viral nucleic acid triggered a destructive inﬂamma-
tory cascade through Toll-like receptor (TLR)3, increasing
parasite survival, and perhaps even predisposing to infectious
metastasis. This ﬁnding was yet another demonstration of
how potently immunological cross-talk is able to alter the
pathogenesis of disease. Indeed, many pathogens are known
to exploit innate cross-talk to evade clearance; for example,
some pathogens produce foreign pathogen-associated molec-
ular patterns (PAMPs) that mimic a different pathogen. These
duplicitous molecules initiate immunological misﬁring, down-
regulating or misguiding the immune attack, and thereby
allowing the pathogen to evade destruction (reviewed in
[12]). This interference, however, need not come from the
same pathogen, and may be caused by a conveniently timed
co-infection, or, indeed, from one nested within the pathogen
itself [8]. Cross-talk is a common and under-appreciated
mechanism underlying opportunistic disease, whereby sec-
ondary pathogens do not just beneﬁt from the resulting
immunodeﬁciency, but also undergo intricate interactions
with intersecting immune pathways. Similarly, metastatic
and virulent leishmaniases have been linked to extrinsic
co-infection as well as to other local immune disturbances.
Predictably, human immunodeﬁciency virus (HIV) infection
predisposes to VL by over 1000-fold (Fig. 1). Although the
major contributor to this correlation is probably the CD4-
FIG. 1. Distribution of 90% of the global leishmaniasis burden and its association with co-infection. Ninety per cent of the world’s leishmaniasis
burden occurs in some of the poorest developing nations. The major symptomatic outcomes are geographically isolated, owing to intrinsic virulence
factors of the infecting parasite and other endemic co-infections such as Leishmania RNA virus (LRV) and human immunodeﬁciency virus (HIV)
(dotted boxes). Complicated cutaneous leishmaniasis, metastatic leishmaniasis and visceral leishmaniasis tend to occur in regions of co-infection.
Nested LRV co-infection is found in some isolates of New World Leishmania Viannia. Inset. Pre-Inca pottery depicting the presence of metastatic
leishmaniasis in Peru in 200–600 CE [75].
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based immune collapse associated with AIDS, recent studies
have shown that Leishmania also beneﬁts from HIV infection
at a cellular level. For instance, macrophages exposed to the
virus were reported to be better hosts for leishmanial
replication, whereby the immune response generated by
HIV’s immunogenic Tat protein dampened oxidative stress
for a subsequent Leishmania infection [13]. Additionally, more
subtle immune disturbances have been associated with the
onset of ML. Clinicians have noted that secondary lesions
tend to develop at sites of prior cutaneous trauma, such as
healing shaving cuts or recently inked tattoos [14], suggesting
the existence of ‘pre-metastatic niches’ that may be seeded as
the secondary sites of leishmanial metastasis.
Of course, although immune interference has the
potential to worsen disease, it is equally capable of alleviating
it. Many antileishmanial agents have at least some immuno-
modulatory activity (reviewed in [15]), or even rely on the
host immune system for their effect. The efﬁcacy of
antimonials, for example, is known to be contingent on
host T-cell function and underlying immune bias [16,17], and
miltefosine is known to activate macrophage functions [18].
Indeed, the patient’s immune activation status can vary
widely, depending on the parasite species and pre-existing
immune cross-talk. Thus, the blind use of immunomodula-
tors, without knowledge of the starting point of each
patient’s inﬂammatory bias, could be the reason for the poor
efﬁcacy of antileishmanial therapy in certain patients. To
allow the effective use of these potent therapeutic tools, it
might help to tailor them to the requirements of each
infection and the individuals who they affect. This ‘immuno-
phenotyping’ (i.e. any of a range of diagnostic techniques
used to deﬁne the immune status of an individual, e.g.
measuring the levels of certain cytokines, cell types,
antibodies, proteins, or delayed-type hypersensitivity (DTH)
responses) approach could serve as a standard preparatory
measure to customize the use of antileishmanials with
immunotherapeutic properties, a potentially valuable inter-
vention for a population with increasingly unpredictable
immunocompetence.
The ImmunologicalWatershedsofCutaneous
Leishmaniases
The slopes of CD4+ T-cell differentiation
Th1/Th2. The pathology of leishmaniasis is so entwined with
host immune processes that the infection is used as a
standard research tool for investigating immunological path-
ways. This was motivated by landmark studies in the late
1980s, following T-cell differentiation in a murine model of
cutaneous leishmaniasis (L. major) [19,20]. These reports
showed that the watershed between lesion recovery and
disease progression was steepled between the slopes of Th1
and Th2 differentiation: where lesion recovery depended on
a Th1 response, while a Th2 bias correlated with disease
progression (Fig. 2). These ‘Th’ designations are given to
CD4+ (T-helper) cells expressing distinct sets of cytokines,
which promote either a cell-mediated response (Th1,
producing proinﬂammatory interferon (IFN)-c and tumour
necrosis factor (TNF)-a) or an antibody-mediated response
(Th2, producing antagonistic interleukin (IL)-4, IL-5, and/or
IL-13). The ‘healing’ Th1 is known to target intracellular
pathogens by increasing oxidative stress in the phagolyso-
some, thus aiding parasite elimination. On the other hand,
the Th2 response is inappropriate for intracellular infection,
perhaps even facilitating leishmanial entry through opsonized
phagocytosis. This ‘Th1 = good/Th2 = bad’ dogma holds
today in many experimental models of CL, but has been
found to be somewhat inadequate to describe human
pathogenesis [21]. Despite this, most immunomodulatory
antileishmanials are still aimed at inducing Th1 or suppressing
Th2: an approach neglecting the role of other T-cell lineages
(Table 1), and is often inappropriate for non-cutaneous and
more complicated disease forms [22]. Although it is clear
that a cell-mediated offensive is essential for parasite
clearance in the majority of leishmanial infections, an overly
potent Th1 response is also known to be responsible for
hyperinﬂammatory collateral damage, where persistent TNF-
a is found in chronic, non-healing lesions [23,24]. Taken
together, these facts reveal a deﬁnitive but narrow window in
which Th1 inﬂammation is beneﬁcial to the host [9] (Fig. 2,
dotted box). On the other hand, Th2 has a more debatable
involvement in disease susceptibility, as the source and
importance of its major cytokines have been questioned in
various experimental models of leishmaniasis [22]. This
variable involvement of Th2 is an indication that susceptibility
may develop from biases in other T-cell polarizations (and
not just Th1 vs. Th2) (Table 1).
The other lineages
Th17, Tfh, Th9 and Tregs have highly variable roles in different
Leishmania infection models, ranging from curative to detri-
mental, or even being found to be completely unimportant
(Table 1). However, the plasticity of these T-cell phenotypes
(i.e. the ability to produce the key effector cytokines of a
mutually exclusive sister population) may underplay or over-
play the extent of their role [25,26]. Provocatively, the
exceptional case of LRV nested infection (whereby an innate
immunogen determines disease severity) may shift the focus
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away from adaptive T-cell lineages and towards chronic
activation of innate pathways and the cross-talk between them.
The fact that different hosts and parasite species give rise to
greatly varying states of immune homeostasis reinforces the
argument for considering personalized immunophenotyping as
a routine procedure for selecting more immunologically
suitable therapeutic options. As this diagnostic luxury is likely
to be unavailable in the resource-restricted ﬁeld, we could
consider using cruder proxies of immune response to, at least,
predict the host’s underlying bias.
The Leishmanin Skin Test (LST): Predicting
Host Immune Biases
Although the type of immune bias depends quite heavily on
parasite factors, an equally important contribution is host-
driven, as shown by the inﬂuence of human genetic polymor-
phisms on susceptibility to leishmanial disease [27–29]. The
LST in which patients are intradermally inoculated with
leishmanial antigen, reveals the diverse immune activity states
found across symptomatic phenotypes of leishmaniasis
(Fig. 2e). A Th1-based DTH causes a welt at the inoculation
site, and could be used as a crude but fair estimate of host Th1
bias. Most patients (90%) with simple, self-healing CL develop a
mildly positive result (>5 mm) in response to a standardized
quantity of leishmanial antigen [30]. The 10% who do not are
seen as having a defect in this response, and could feasibly
beneﬁt from standard Th1-inducing antileishmanials. In meta-
static disease, however, there are hardly any exceptions to
positive reactivity; a large, inﬂamed welt develops, indicative of
the destructive allergic reaction that underlies its symptomatic
outcome. Intriguingly, mucocutaneous and ML lesions often
have disproportionately few or even undetectable levels of
parasite [31], heavily contrasting with the severe inﬂammation.
Nevertheless, the same proinﬂammatory drug regimens are
used to treat patients already suffering from debilitating
swelling. Although many of these drugs have alternative
parasitotoxic mechanisms, the morbidity of metastatic leish-
maniasis could be signiﬁcantly reduced through the (seemingly
FIG. 2. The immunological watersheds of cutaneous leishmaniasis. The various symptomatic outcomes (a) of cutaneous leishmaniasis (CL) range
from self-healing to metastatic leishmaniasis (ML), and result from biases in the human immune response. These immunological watersheds (b) are
formed by the slopes of T-cell reactivity, which are differentially activated by the various Leishmania species (c) and then further inﬂuenced by other
immunological disturbances (d), such as co-infection. Only a narrow window of Th1 reactivity (dotted box) results in self-healing disease. Treatment
strategies (Rx) could be potentially tailored to approach this window. Here, three different Rx are categorized with each of the major symptomatic
outcomes. The varying results of the leishmanin skin test (e) can serve as a crude clinical indication of immune biases, and then be used to better
guide immunotherapeutic treatment options. Watershed: a threshold point dividing two opposing possibilities. IFN, interferon; IL, interleukin; PKDL,
post-kala-azar dermal leishmaniasis, a type of diffuse leishmaniasis occurring as a complication of visceral disease.
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counterintuitive) use of anti-inﬂammatory agents. Thus far, the
few clinical trials performed have produced some encouraging
results [32,33], showing a place for carefully administered
immunosuppression as co-therapy in severe leishmaniasis.
On the distant extreme of the Th1 slopes lie systemic
infections such as post-kalar-azar dermal leishmaniasis and
severely diffuse cutaneous disease. These tend to give false-
negative results in the LST, owing to an immune response that
has been exhausted into anergy. It is generally accepted that a
major cause of susceptibility to systemic leishmaniasis is an
excess of immunosuppressive IL-10, and studies in mice in
which the immune response has been ‘unblocked’ with anti-IL-
10 have shown some promise [34,35].
Although these broad generalizations on T-cell bias can be
linked to symptomatic groupings (as proposed in Fig. 2a), HIV
co-infection and other immune disturbances are shifting the
symptomatic watersheds to unexpected positions (Fig. 2d),
thus supporting the suggestion of an individualized approach to
therapeutics, such as immunophenotyping. As leishmaniasis is
often endemic in economically compromised regions, a central
concern of any diagnostic/therapeutic intervention is its
ﬁnancial feasibility. A simple and cost-effective approach such
as the LST could be easily implemented in such areas. Here, the
measurement of welt (induration) size has already been shown
to vary greatly between patients having different outcomes,
levels of drug responsiveness, and immune status [36,37].
Although much further research is needed to determine more
concrete correlations and to standardize the procedure, the
LST could have an untapped and complementary potential in
leishmanial diagnostics. Additionally, some scattered correla-
tions between the cellular composition of the lesion and
susceptibility have been found, but, again, this needs further
mass and epidemiological screening to be of any use. Even if
precise immunophenotyping proves too complex, screening for
potential sources of immune cross-talk that could affect disease
progression may allow us to better estimate the underlying
immune background and choose therapies that may direct the
cross-talk towards a healing phenotype.
To exploit this cross-talk and minimize collateral tissue
damage while eliminating the parasite, a deeper understanding
of the possible immune interactions between the parasite and
its common co-infections is needed.
Pathogenic Cross-Talk
Rather than being just a state of immunological confusion, the
cross-talk network is an intricate means of regulation,
synergizing weak stimuli and reigning in collateral damage
[38–40]. Leishmania is already well known to exploit these
intersections with a multitude of evasion tactics, working to
reduce its detection and prolong its survival. Most of the
described mechanisms show the coopting of inhibitory recep-
tors that dampen cellular immunity or misguide the attack.
One well-described method appropriates the complement
system, which is among the ﬁrst of the parasite–host
TABLE 1. The roles of the ‘other’ CD4+ T-helper cell lineages in human leishmaniasis
IL-6
IL-17A/F
IL-23
IL-23R
Maintenance
IL-1
Th17TGF-β
IL-10
IDOTreg
IL-10
TGF-β
IL-9
IL-4
IL-10Th9
IL-4
IL-21
IFNα/β
TGF-β
IL-4
IL-21TfhICOS
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interactions. Seemingly in conﬂict with the deﬁnition of
‘evasion’, Leishmania, of all species, potently and selectively
activates complement. This selectivity is also found between
the various stages of the parasite, whereby promastigotes and
amastigotes can differentially target the human complement
receptors CR1 and CR3 to suit their distinct living conditions
[41]. This cunning use of cross-talk increases phagocytosis
through opsonized complement receptor-mediated uptake,
and decreases the intensity of the oxidative burst within the
phagosome. It is so pivotal to pathogenesis that genetic
ablation of the complement receptor C5aR renders mice
resistant to infection with L. major (even the notoriously
susceptible Th2-prone BALB/c mice) [42].
Similar strategies are used by numerous other pathogens,
and so it can be easily imagined that their concurrent infection
with leishmaniasis could worsen disease outcome. Co-infec-
tions could thus constitute an important method of leishmanial
immune evasion. Indeed, cutaneous lesions often co-host
bacterial and fungal infestations, which are mostly dismissed as
opportunistic disease. A recent study on a Pakistani patient
sample showed a 60% incidence of bacterial co-infection, and
at least 20% of these co-infections were caused by strepto-
coccal groups [43] that are known to disrupt TLR signalling
through the innate sialic acid-binding immunoglobulin-like
lectins receptor (Siglec) [44]. Coincidently, Siglec ligands also
appear on the membranes of L. donovani parasites, and have
been shown to signiﬁcantly increase their phagocytosis and
virulence [45]. This supports a hypothesis that bacteria co-
infecting CL lesions could alter leishmanial pathogenesis. More
convincing is a pioneering study published by the group of
Belkaid, who showed that tissue-resident commensals are
integral to antileishmanial immunity [46].
A thus far under-explored source of cross-talk may be co-
infection within the vector of Leishmania, the sand ﬂy. The sand
ﬂy midgut is home to a range of bacterial, fungal and viral
species [47], which have been described as competitive co-
infections that reduce leishmanial transmission [48,49].
Recently, the potential mechanism of this interaction was
linked to an innate immune response in the sand ﬂy, whereby
the experimental ingestion of a common bacterial pathogen
caused a surge of oxidative stress in the midgut, to which
Leishmania is especially sensitive [50]. An interesting avenue of
discussion may be whether the presence of these co-infections
(and thus constant exposure to low-level oxidative stress)
could act as a training ground for the hostile conditions in the
mammalian phagolysosome, selecting more oxidative stress-
resistant, virulent parasites.
This vector-parasite cross-talk continues in the human host,
where sand ﬂy saliva is known to contribute to the local immune
response against the parasites. Interestingly, saliva has had a
variable effect on disease progression, ranging from detrimental
[51–53] to curative [54,55]. This variability seems to depend on
both the parasite species and the proteinaceous constituents of
the saliva. A study exemplifying this latter claim showed that two
different protein isolates of the same salivary extract had
opposing effects on disease progression in a mouse model [56].
Whether the midgut co-infections (or their immunogenic
components) contribute the immunomodulatory properties of
sand ﬂy saliva is still unknown. Interestingly, both the type of co-
infection [57] and the immunogenicity of sand ﬂy saliva [58]
depend on the substrate of larval development, as differences
were seen between ‘cleaner’ laboratory conditions and those
found in the wild. These studies reveal a clear sensitivity of
Leishmania to immune disturbances, thus supporting personal-
ized immunomodulation as a therapeutic prospect.
Various other commonly occurring co-infections are known
to cause similar interference (adenoviruses [59], Mycobacte-
rium tuberculosis [60,61], Mycobacterium leprae [62], Candida
albicans, and Helicobacter pylori [63]), and some of these co-
infections are physiologically important for mucocutaneous
ML, as they are frequently present in mucosal tissues, and
could perhaps seed the site for metastatic infection (Fig. 3).
HIV co-infection
Because the CD4+ collapse that occurs in AIDS increases
susceptibility to leishmaniasis by over 1000-fold [64], it is
difﬁcult to ﬁnd the comparatively minor contribution of cross-
talk important. However, with the advent of highly active
antiretroviral treatment, more patients are avoiding the onset
of AIDS and are able to maintain relatively normal levels of
CD4+ T-cells, making cross-talk between HIV and its co-
infections of increasing interest (reviewed in [65]). HIV
patients with leishmaniasis are known to have a potent Th2
bias, which drastically worsens their disease [66,67]. Leish-
mania also beneﬁts HIV, enhancing viral transcription by
inducing the host gene encoding nuclear factor-jB (a host gene
that HIV hijacks as its promoter) [68]. Coincidently, these
pathogens infect common cells of the monocyte lineage
(macrophages and dendritic cells), and so their interaction
may be much more direct than those driven through T-cell
intermediates. In vitro studies have shown that HIV-infected
macrophages more readily engulf leishmanial parasites [69,70],
and also that the HIV Tat protein primes these cells for
enhanced leishmanial survival [13]. Similarly, the lipophospho-
glycan on the surface of Leishmania promastigotes enhances
HIV replication [71], albeit inhibitory for viral uptake [72].
LRV: a nested co-infection
The Russian doll model of hyperpathogenesis proposed by our
group [8] describes a unique situation of pathogenic cross-talk
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(hyperpathogenesis refers to the situation whereby a pathogen
living endosymbiotically within another pathogen increases
disease virulence, such as is the case for LRV found within
certain strains of L. Viannia). Although viral hyperpathogens
have been largely overlooked as independent immunogenic
entities, the recognition of viral components is well described
as well as potent. For instance, the molecular patterns in viral
nucleic acid are able to trigger potent inﬂammatory cascades
through a variety of innate receptors. TLRs, Rig-like receptors
and Nod-like receptors stand out as major sentinels of viral
recognition, giving way to antiviral responses and inﬂamma-
some activation, which can antagonize and even overpower
those generated by their microbial host. This immunological
misﬁring can have important consequences for disease
pathogenesis, such as for the development of complicated or
metastatic leishmaniasis.
In the case of the LRV hyperpathogen, only TLR3 has been
implicated, and was the ﬁrst study describing this receptor as
having a detrimental role in leishmaniasis. Cross-talk between
these innate immunogens increases the levels of inﬂammatory
cytokines, releasing a burst of IFN-b, which seems to be at
the heart of this destructive inﬂammatory cycle. A further co-
infection on top of this nested one could drastically
compound the situation (Fig. 3). Considering all the possible
permutations of these immunological cross-wires, it is
important to ﬁnd predictable outcomes of simultaneous
immune events to facilitate the choice of appropriate
therapeutic intervention.
FIG. 3. Pathogenic Toll-like receptor (TLR) cross-talk in leishmanial co-infections. Green: the self-healing response. Pathogen-associated molecular
patterns (PAMPs) on the surface of Leishmania, lipophosphoglycan (LPG) and a lipopolysaccharide (LPS) like complex called p8 activate TLR2 and
TLR4, respectively. This elicits a cell-mediated (Th1) immune response, as well as inducing oxidative stress for intracellular parasite elimination.
Orange: pathogenic TLR3 cross-talk from the Leishmania RNA virus (LRV) nested infection. LRV is released within the phagolysosome, stimulating
TLR3 with its dsRNA. This induces a destructive inﬂammatory cascade led by interferon (IFN)-b, skewing the T-cell balance towards a pathogenic
destructive proﬁle (lower right box). Blue: cross-talk from extrinsic infections. Stimulation of dendritic cell-speciﬁc intracellular adhesion molecule 3
grabbing non-integrin (DC-sign) by pathogens such as human immunodeﬁciency virus (HIV) and Mycobacterium tuberculosis blocks TLR2/4-stimulated
intracellular parasite killing, as well as skewing the immune response to an ineffective antibody-mediated one (lower left box). For LRV-containing
parasites, DC-sign stimulation could synergize with TLR3, thereby worsening hyperinﬂammation and perhaps predisposing the patient to atypical
outcomes. The mannose found in Candida albicans has a similar effect [76,77]. Red: interference by highly active antiretroviral treatment (HAART) as
potentially seeding ML. HAART therapy was recently shown to hypersensitize the mucosal epidermis to non-TLR3 dsRNA recognition [78], which
provides a potential reason for the increased incidence and intensity of ML in patients co-infected with HIV [79]. NOD2, RIG-I and MDA5 are innate
pattern recognition receptors (PRRs) that are able to recognize dsRNA and feed into the same IFN-b-dependent inﬂammatory cascade. IL,
interkeukin; IFNAR, type 1 interferon receptor; TNF, tumour necrosis factor; MR, mannose receptor.
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TABLE 2. Mechanisms of promising immunotherapeutics
overall effecta
overall effectb
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Perspectives: Tailored Immunotherapeutics
Current therapeutic interventions in leishmaniasis are not
only limited in efﬁcacy, but also have a restricted patient
base, owing to the possibility of severe side effects
(Table 2A). They have been further hindered by the emer-
gence of resistance to some major ﬁrst-line drugs, particu-
larly concerning increased parasite persistence under
oxidative stress, a mechanism on which most antileishmanials
rely [73]. Although antileishmanials are primarily parasitotox-
ic, many of these drugs have also been shown to directly and
indirectly target the human immune system, meaning that
deteriorating host immunocompetence could alter drug
efﬁcacy. Indeed, the wave of HIV across Leishmania-endemic
areas has aided the rise of severe and atypical leishmaniases
that are increasingly refractory to current therapies. Until
now, no ﬁxed or dependable therapeutic solution has been
found for the treatment of these atypical symptomatic
outcomes of extreme or persistent inﬂammation, and most
clinical approaches simply entail increasing the dosage or
duration of the already problematic regimens [1]. Although
there is already a tentative move towards combination
therapy, the drugs prescribed have widely varying immuno-
modulatory mechanisms. Thus, using these drugs without
basis on the underlying position of immune homeostasis may
be the reasoning behind their variable efﬁcacy. Indeed, the
immunomodulatory effects of four of the ﬁve most com-
monly used drugs increase Th1-based inﬂammation
(Table 2A). For instance, the widely used antimonial therapy
has been shown to be ineffective in mice without a functional
T-cell response or, indeed, without key Th1 effector
cytokines such as IFN-c (reviewed in [74]).
Following the model proposed above (Fig. 2), antileishma-
nial drugs with common immunomodulatory mechanisms can
be grouped to suit the various symptomatic outcomes of
leishmaniasis. This potential categorization is summarized
below for current antileishmanials (Table 2A) and for those
showing experimental promise as future immunomodulatory
co-therapies (Table 2B). Immune bias was extrapolated from
broad trends described among the various leishmaniases and
thereafter ascribed to a treatment category as follows:
1. Simple CL (caused by the L. Leishmania subgenus), warrant-
ing the pro-Th1/anti-Th2 therapy (Rx1)
2. Chronic and complicated CL or ML (caused by either
L. Leishmania or L. Viannia parasites), for which an anti-
inﬂammatory co-therapeutic regimen is proposed (Rx2)
3. Systemic disease such as VL, post-kalar-azar dermal leish-
maniasis and diffuse infection (caused primarily by Leishmania
donovani and Leishmania infantum or by various parasites in
HIV-co-infected patients) that may beneﬁt from a combina-
tion of IL-10 reduction and Th1 reactivation (Rx3).
Of course, drugs whose major mechanisms are directly
parasitotoxic (Rx toxic) are potentially effective for any
leishmanial infection, but species-speciﬁc susceptibility would
have to be further investigated before they could be included
in subcategories. For now, they stand as a wild cards for
inclusion in combination therapy. Although the (rather under-
studied) immunomodulatory effects of antileishmanials were at
times quite weak, and possibly outweighed by as yet undeﬁned
parasitotoxicity, a trend for correlation with the model of
categorization could be seen. This reinforces the promise of
this therapeutic framework, whereby drugs are tailored to
counter the unique immunological misﬁre of each type of
leishmaniasis.
Even if individualized immunophenotyping proves too
complex or expensive to introduce into the ﬁeld, screening
for immunological disturbances such as co-infection could
serve to guide therapeutics. In this way, predicable immune
patterns in HIV and LRV infection could funnel patients into
appropriate treatment groups.
Understanding these intersecting immune pathways of
leishmaniasis and its co-infections may enable us to identify
new therapeutic targets that work by untangling the immuno-
logical cross-wires of pathogenic cross-talk.
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